Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT05743933
Recruiting Observational

Chongqing Adrenogenic Autonomic Cortisol Secretion Cohort Study

NCT05743933 · tracked via the Priya Life Science China tracker
Sponsor
Chongqing Medical University
Phase
Observational
Started
2023-02-17
Last updated
2026-09-24

Condition(s) studied

DiagnosisTreatmentAdrenogenic Autonomic Cortisol Secretion

Study summary

To investige the etiology, pathogenesis, diagnosis and treatment of adrenogenic autonomic cortisol secretion in Chinese adults.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * CT examination revealed adrenal nodules (maximum diameter ≥10mm); * Serum cortisol \> 50nmol/L after 1mg dexamethasone inhibition test (1mg-DST). Exclusion Criteria: * Patients with primary aldosteronism (PA), pheochromocytoma, adrenal metastatic carcinoma, congenital adrenal hyperplasia (CAH), ganglionic neuroma/paraganglioma, schwannoma, adrenal hematoma and those with no definite diagnosis were evaluated by clinical and endocrine function. * Patients with serious underlying diseases (such as liver and kidney failure, acute severe infection, etc.) that may affect the function of the hypothalamic-pituitary-adrenal axis (HPA axis); Pregnancy. * Patients with a history of alcoholism, fatigue, trauma, infection, depression, glucocorticoid use, and other drugs affecting the function of the hypothalamic-pituitary-adrenal axis. * Patients who are not willing to participate in and complete this study refuse to sign the written informed consent for this study.

Primary outcome measure(s)

  • SUVmax value of PET-CT — 10 years
    To explore the value of 68\[Ga\]-Pentixafor PET-CT in the diagnosis of MACS

Trial sites (1)

FacilityCityRegionStatus
Department of Endocrinology, Sichuan-Chongqing Joint Key Laboratory of Metabolic Vascular Diseases, Chongqing Key Laboratory of Translational Medicine in Major Metabolic Diseases, The First Affiliated Hospital of Chongqing Medical University Chongqing Chongqing Municipality Recruiting

More Chongqing Medical University trials in China

Endoscopic Ultrasound-Guided Ethanol Ablation for Aldosterone-Producing Adenoma Starting soon
Ultrasound-Guided Nerve Hydrodissection for Diabetic Lower Limb Entrapment Neuropathy Recruiting
Shortwave Intervention for Diabetic Peripheral Neuropathy. Recruiting
Chongqing Diabetes Registry Study Recruiting
High PEEP in Noninvasive Ventilation Patients With Pneumonia or ARDS Recruiting

Other trials for the same condition

Efficacy Safety BaiDiZiYin ShenQiYiFei Adjunctive Treatments Pulmonary Tuberculosis Recruiting
Rituximab for the Treatment of New-onset AChR-Myasthenia Gravis Active, not recruiting
Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial Recruiting
The Study of ENB With Ultra-thin Cryobiopsy in the Diagnosis of Peripheral Pulmonary Nodules Enrolling by invitation
The Study on the Accuracy of Peri-implant Probing and Related Influencing Factors Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05743933 on ClinicalTrials.gov ↗ ← All trials in China